Showing results (261-270 of 1,393) with videos related to

Sort By:
Pageof 140
JCO Precision Oncology|September 10, 2025
Identification of Targetable EGFR Mutations in Ovarian CancerArjan Gower, Susan Win, Rituparna Ganguly, et al.
JCO Precision Oncology|September 19, 2025
Prognostic Significance of RB1 Alterations on Outcomes in Metastatic Prostate CancerRuben Raychaudhuri, Isla P Garraway, Kara N Maxwell, et al.
JCO Precision Oncology|September 19, 2025
Patient-Reported Outcomes From Males Regarding Germline Testing for Prostate Cancer: Results From the PROGRESS RegistryStacy Loeb, Scott W Keith, Laura Gross, et al.
JCO Precision Oncology|September 24, 2025
Using Circulating Tumor DNA-Based Molecular Residual Disease Detection for Postoperative Monitoring in Early-Stage Uterine CancerPeter W Ketch, Carly Bess Scalise, Fernando Recio, et al.
JCO Precision Oncology|September 19, 2025
Clinical Benefit From Molecularly Guided Cancer Care: A Matching-Adjusted Indirect Comparison of Larotrectinib Versus Standard of CareCarsten Bokemeyer, Keith R Abrams, Jesus Garcia-Foncillas, et al.
JCO Precision Oncology|September 17, 2025
Rare Variants Associated With Pediatric Cancer Treatment-Related Second Malignant Neoplasm RiskClaire Ducos, Brice Fresneau, Filippo Rosselli, et al.
JCO Precision Oncology|June 17, 2025
Microsatellite Peak Shifts in Polymerase Chain Reaction-Based Fragment Length Data Correlate With Microsatellite Instability Degree and Vary With Mismatch Repair Gene Defects and Tumor SizeNoah C Helderman, Saskia Haupt, Fabian Strobel, et al.
JCO Precision Oncology|June 11, 2025
Real-World Outcomes of Molecular Tumor Board Treatment RecommendationsFederico Nichetti, Marta Brambilla, Matteo Duca, et al.
JCO Precision Oncology|May 29, 2025
PD-L1 Expression in Biliary Tract Cancer: Comparison Across Antibody Clones and Role as a Predictor of Response to Chemoimmunotherapy: A Meta-AnalysisJuan J Juarez-Vignon Whaley, Soravis Osataphan, Ben Ponvilawan, et al.
JCO Precision Oncology|March 1, 2024
Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Receiving Palbociclib: Results From the TREnd TrialIlenia Migliaccio, Dario Romagnoli, Francesca Galardi, et al.
Pageof 140